- Home
- TOP vs BNR Comparison
TOP vs BNR Comparison
Compare TOP & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOP
- BNR
- Stock Information
- Founded
- TOP 2015
- BNR 2014
- Country
- TOP Singapore
- BNR China
- Employees
- TOP N/A
- BNR N/A
- Industry
- TOP Investment Bankers/Brokers/Service
- BNR Medical Specialities
- Sector
- TOP Finance
- BNR Health Care
- Exchange
- TOP Nasdaq
- BNR Nasdaq
- Market Cap
- TOP 43.0M
- BNR 38.3M
- IPO Year
- TOP 2022
- BNR 2020
- Fundamental
- Price
- TOP $1.16
- BNR $9.18
- Analyst Decision
- TOP
- BNR
- Analyst Count
- TOP 0
- BNR 0
- Target Price
- TOP N/A
- BNR N/A
- AVG Volume (30 Days)
- TOP 22.1K
- BNR 48.7K
- Earning Date
- TOP 08-13-2025
- BNR 09-08-2025
- Dividend Yield
- TOP N/A
- BNR N/A
- EPS Growth
- TOP N/A
- BNR N/A
- EPS
- TOP N/A
- BNR N/A
- Revenue
- TOP $3,329,256.00
- BNR $74,862,782.00
- Revenue This Year
- TOP N/A
- BNR $136.32
- Revenue Next Year
- TOP N/A
- BNR N/A
- P/E Ratio
- TOP N/A
- BNR N/A
- Revenue Growth
- TOP N/A
- BNR 5.20
- 52 Week Low
- TOP $1.00
- BNR $2.18
- 52 Week High
- TOP $1.94
- BNR $11.12
- Technical
- Relative Strength Index (RSI)
- TOP 47.23
- BNR 60.95
- Support Level
- TOP $1.13
- BNR $7.83
- Resistance Level
- TOP $1.18
- BNR $9.10
- Average True Range (ATR)
- TOP 0.03
- BNR 0.87
- MACD
- TOP 0.00
- BNR -0.13
- Stochastic Oscillator
- TOP 23.08
- BNR 43.26
About TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.